Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer

• DOI: 10.1089/thy.2023.0521
• Publication Date: 2023-12-20T06:58:38Z
• Authors: Takahito Kimura; Woo Kyung Lee Doo...; Michael Kruhlak; Li Zhao; Eunmi Hwang; Xuguang Zhu; Binwu Tang; Karen M. Wolcott; Sheue-yann Cheng
• Keywords: Trametinib; Anaplastic thyroid cancer; Dabrafenib

Anaplastic thyroid cancer (ATC) is highly aggressive and has very limited treatment options. Recent studies suggest that stem cell (CSC) activity in ATC could underlie this recurrence resistance to treatment. The recent approval by the U.S. Food Drug Administration of combined BRAF MEK inhibitors for patients shown some efficacy harboring